• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Vidora Micro 3mg/0.02mg, 84 tablets — Made in Spain — Free Delivery

    Vidora Micro 3mg/0.02mg, 84 tablets — Made in Spain — Free Delivery


    Brand: Laboratorios Leon Farma
    Product Code: Vidora Micro
    Availability: 5-10 Days
    $41.51
    Add to Cart

    Product description 

    Vidor micro tablets are indicated for oral contraception.

    Compound

    Active ingredients: drospirenone, ethinylestradiol;
    1 blister contains 28 tablets (21 pink active tablets and 7 white placebo tablets);
    1 pink coated tablet contains drospirenone 3.0 mg and ethinyl estradiol 0.02 mg;
    Excipients: lactose, corn starch, povidone K-30, croscarmellose sodium, polysorbate 80, magnesium stearate, Opadry® II pink (polyethylene glycol, polyvinyl alcohol, titanium dioxide (E 171), talc, iron oxide yellow (E172), iron oxide red (E172), iron oxide black (E172)).
    1 white coated tablet (placebo) contains:
    Excipients: lactose, povidone K-30, magnesium stearate, Opadry® II white (polyvinyl alcohol (hydrolyzed part), titanium dioxide (E 171), macrogol 3350, talc (E 553b)).

    Contraindications

    Combined hormonal contraceptives (CHCs) should not be used if any of the following conditions are present. If any of these conditions occur for the first time during the use of CHC, the preparation should be stopped immediately.
    Presence or risk of developing venous thromboembolism (VTE):
    • current VTE, particularly due to anticoagulant therapy or a history of (eg, deep vein thrombosis (DVT) or pulmonary embolism (PE));
    • known hereditary or acquired predisposition to VTE, such as resistance to activated protein C (including factor V Leiden mutation), antithrombin-III deficiency, protein C deficiency, protein S deficiency;
    • major surgical interventions with prolonged immobilization;
    • high risk of VTE due to the presence of multiple risk factors.
    The presence or risk of developing arterial thromboembolism (ATE):
    • the presence of ATE at present or in history (eg, myocardial infarction) or the presence of prodromal symptoms (eg, angina pectoris);
    • current or past cerebrovascular accident, presence of prodromal symptoms (eg, transient ischemic attack (TIA));
    • known hereditary or acquired tendency to ATE, such as hyperhomocysteinemia and antibodies to phospholipids (antibodies to cardiolipins, lupus anticoagulant);
    • migraine with a history of focal neurological symptoms;
    • high risk of ATE due to the presence of multiple risk factors or due to the presence of one serious risk factor, such as:
    • diabetes mellitus with vascular complications;
    • severe arterial hypertension;
    • severe dyslipoproteinemia.
    Current or history of severe liver disease until liver function tests have returned to normal.
    Severe renal failure or acute renal failure.
    The presence of liver tumors at present or in history (benign or malignant).
    Known or suspected malignant tumors (for example, of the genital organs or mammary glands) that are dependent on sex hormones.
    Vaginal bleeding of unknown etiology.
    Hypersensitivity to the active substances or to any of the components of the preparation.
    The preparation Vidora micro is contraindicated when used simultaneously with preparations containing ombitasvir / paritaprevir / ritonavir and dasabuvir

    Mode of application

    Tablets should be taken daily according to the order indicated on the package, at about the same time, with a small amount of liquid if necessary. Tablets should be taken continuously. The preparation is taken 1 tablet / day for 28 days in a row. Taking tablets from each subsequent package should be started the next day after the end of the previous package. Usually, withdrawal bleeding starts 2-3 days after the start of the placebo pills (last row) and may not end before the pills from the next pack start.

    Application features

    pregnant
    The preparation is contraindicated for use during pregnancy.
    Children
    The preparation is indicated for use as prescribed by a doctor only after the onset of stable menstruation.
    Drivers
    No studies have been conducted on the effect of Vidora micro on the reaction rate when driving vehicles or working with other mechanisms.

    Overdose

    So far, there are no data from clinical studies regarding an overdose of Vidora micro tablets. Based on general experience with the use of COCs, overdose may cause nausea, vomiting, and in young girls, vaginal bleeding. Vaginal bleeding can occur in girls even before menarche in case of inadvertent/accidental use of the preparation. There is no specific antidote; treatment should be symptomatic.

    Side effects

    Women taking CHCs were at an increased risk of developing venous or arterial thrombotic and thromboembolic events, including myocardial infarction, stroke, TIA, venous thrombosis, and PE.

    Interaction

    The use of contraceptive steroids may affect the results of some laboratory tests, such as biochemical parameters of liver, thyroid, adrenal and kidney function, plasma concentrations of transport proteins such as corticosteroid-binding globulin, plasma concentrations of lipid/lipoprotein fractions, indicators of carbohydrate metabolism, coagulation and fibrinolysis. Usually these changes are within the normal range. Drospirenone increases the activity of renin and aldosterone in blood plasma, induced by its moderate antimineralocorticoid activity.

    Storage conditions

    Keep out of the reach of children at a temperature not exceeding 25°C.
    Shelf life - 3 years.

    There are no reviews for this product.
    VEV Healthcare Store © 2017